Visual Acuity and Durability Outcomes of Faricimab Compared With Other Antivascular Endothelial Growth Factor Agents Within Routine Clinical Practice for Neovascular Age-Related Macular Degeneration

Abstract

Purpose: To compare the visual acuity (VA) outcomes and dosing intervals of faricimab with those of other antivascular endothelial growth factor agents in treatment-naïve and treatment-experienced eyes with neovascular age-related macular degeneration (nAMD). Methods: De-identified electronic medical records (Vestrum Health treatment and outcomes database) of patients with nAMD treated with bevacizumab, ranibizumab, aflibercept, or faricimab between January 2021 and December 2023 were included. Mean VA change and mean number of days between injections were collected through 6 injections for treatment-naïve eyes and through 2 injections for treatment-switched eyes. Results: A total of 736 treatment-naïve eyes receiving faricimab experienced nonsignificantly lower VA gains than all other drugs; 5467 eyes switched to faricimab demonstrated lower VA gains relative to other drugs. This includes significantly lower gains than aflibercept or bevacizumab when switched from ranibizumab (P < .01). Bevacizumab achieved the highest VA gains—significantly more than aflibercept (P < .01) in the treatment-naïve cohort and significantly more than faricimab and aflibercept when switched from ranibizumab (P < .01). After adjusting for significant VA differences at baseline and at the switch date, all drugs displayed similar VA gains in both cohorts. Compared with all other drugs, faricimab provided up to 4 additional days on average between injections and had the highest proportion of eyes extended over 50 days between the final 2 injections for both cohorts. Relative to aflibercept and ranibizumab, these injection frequencies for faricimab were significantly longer (P < .01). Conclusions: Treatment-naïve and treatment-experienced nAMD eyes receiving faricimab demonstrated VA gains and minimally longer injection intervals, comparable to other antivascular endothelial growth factor agents.

Keywords

Get full access to this article

View all access options for this article.

References

Campbell

Bronskill

Bell

Paterson

Whitehead

Gill

SS.

Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis. Arch Ophthalmol. 2010;128(3):359-362. doi:10.1001/archophthalmol.2010.19

Ciulla

Bracha

Pollack

Williams

DF.

Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States. Ophthalmol Retina. 2018;2(12):1179-1187. doi:10.1016/j.oret.2018.06.004

Ciulla

Hussain

Pollack

Williams

DF.

Visual acuity outcomes and anti–vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49 485 eyes. Ophthalmol Retina. 2020;4(1):19-30. doi:10.1016/j.oret.2019.05.017

Ciulla

Hussain

Taraborelli

Pollack

Williams

DF.

Longer-term anti-VEGF therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema: clinical outcomes in 130 247 eyes. Ophthalmol Retina. 2022;6(9):796-806. doi:10.1016/j.oret.2022.03.021

Khan

Aziz

Shafi

Abbas

Khanani

AM.

Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab. Cells. 2020;9(8):1869. doi:10.3390/cells9081869

Khanani

Patel

Ferrone

, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY Phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138(9):964-972. doi:10.1001/jamaophthalmol.2020.2699

Heier

Khanani

Quezada Ruiz

, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729-740. doi:10.1016/S0140-6736(22)00010-1

Wykoff

Abreu

Adamis

, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741-755. doi:10.1016/S0140-6736(22)00018-6

Khanani

Kotecha

Chang

, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914-926. doi:10.1016/j.ophtha.2024.02.014

10.

Khanani

Aziz

Khan

, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study — 6 month results. Eye (Lond). 2023;37(17):3574-3581. doi:10.1038/s41433-023-02553-5

11.

Penha

Masud

Khanani

, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitreous. 2024;10(1):5. doi:10.1186/s40942-024-00525-9

12.

Gregori

Feuer

Rosenfeld

PJ.

Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046-1050. doi:10.1097/IAE.0b013e3181d87e04

13.

Patel

Talks

Salvo

Pearce

De Silva

SR.

Real-world use of faricimab to treat nAMD patients in the UK (FARWIDE study). Paper presented at: American Society of Retinal Specialists Annual Meeting; Seattle; 2023.

14.

Varma

Talks

de Salvo

, et al. Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with neovascular age-related macular degeneration (nAMD) in the UK: FARWIDE-nAMD. Invest Ophthalmol Vis Sci. 2024;65(7):4905.

15.

Tabano

Borkar

, et al. Real-world clinical and anatomical outcomes in patients with neovascular age-related macular degeneration (nAMD) treated with faricimab: the FARETINA-AMD study. Invest Ophthalmol Vis Sci. 2024;65(7):2113.

16.

Borkar

Tabano

Garmo

, et al. FARETINA-AMD- Early treatment patterns and outcomes in patients with neovascular age-related macular degeneration initiating faricimab: an IRIS RegistryTM analysis. Invest Ophthalmol Vis Sci. 2023;64(8):2218.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB